UA80092C2 - Granular preparations of gaboxadol, process for the preparation thereof and pharmaceutical composition - Google Patents
Granular preparations of gaboxadol, process for the preparation thereof and pharmaceutical composition Download PDFInfo
- Publication number
- UA80092C2 UA80092C2 UA20031110120A UA20031110120A UA80092C2 UA 80092 C2 UA80092 C2 UA 80092C2 UA 20031110120 A UA20031110120 A UA 20031110120A UA 20031110120 A UA20031110120 A UA 20031110120A UA 80092 C2 UA80092 C2 UA 80092C2
- Authority
- UA
- Ukraine
- Prior art keywords
- product according
- filler
- melt
- granular product
- gaboxadol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 229950004346 gaboxadol Drugs 0.000 title claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 239000007787 solid Substances 0.000 claims abstract description 10
- 239000002552 dosage form Substances 0.000 claims abstract description 9
- 238000002844 melting Methods 0.000 claims description 25
- 230000008018 melting Effects 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 19
- 239000011230 binding agent Substances 0.000 claims description 18
- 239000000945 filler Substances 0.000 claims description 18
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 229920002261 Corn starch Polymers 0.000 claims description 9
- 239000008120 corn starch Substances 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000012943 hotmelt Substances 0.000 claims description 6
- 239000008118 PEG 6000 Substances 0.000 claims description 5
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 239000012458 free base Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000000155 melt Substances 0.000 claims description 2
- 238000012876 topography Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 4
- 238000007909 melt granulation Methods 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 description 18
- 238000005469 granulation Methods 0.000 description 15
- 230000003179 granulation Effects 0.000 description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000003979 granulating agent Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000001506 calcium phosphate Substances 0.000 description 6
- 235000011010 calcium phosphates Nutrition 0.000 description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- -1 for example Chemical class 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000005260 corrosion Methods 0.000 description 4
- 230000007797 corrosion Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000004135 Bone phosphate Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200100817 | 2001-05-21 | ||
| PCT/DK2002/000332 WO2002094225A1 (en) | 2001-05-21 | 2002-05-17 | Granular preparations of gaboxadol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA80092C2 true UA80092C2 (en) | 2007-08-27 |
Family
ID=8160520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20031110120A UA80092C2 (en) | 2001-05-21 | 2002-05-17 | Granular preparations of gaboxadol, process for the preparation thereof and pharmaceutical composition |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20040157876A1 (pt) |
| EP (1) | EP1389091A1 (pt) |
| JP (1) | JP2004530695A (pt) |
| KR (1) | KR20030097890A (pt) |
| CN (1) | CN1511026A (pt) |
| AR (1) | AR033896A1 (pt) |
| AU (1) | AU2002338855B2 (pt) |
| BG (1) | BG108441A (pt) |
| BR (1) | BR0209834A (pt) |
| CA (1) | CA2447603A1 (pt) |
| CZ (1) | CZ20033269A3 (pt) |
| EA (2) | EA200700703A1 (pt) |
| HR (1) | HRP20030950A2 (pt) |
| HU (1) | HUP0400051A2 (pt) |
| IL (1) | IL158733A0 (pt) |
| IS (1) | IS7020A (pt) |
| ME (1) | MEP6308A (pt) |
| MX (1) | MXPA03010596A (pt) |
| NO (1) | NO20035146L (pt) |
| NZ (1) | NZ547636A (pt) |
| PL (1) | PL366541A1 (pt) |
| SK (1) | SK15542003A3 (pt) |
| UA (1) | UA80092C2 (pt) |
| WO (1) | WO2002094225A1 (pt) |
| YU (1) | YU92103A (pt) |
| ZA (1) | ZA200308594B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003510266A (ja) * | 1999-09-28 | 2003-03-18 | ハー・ルンドベック・アクチエゼルスカベット | 溶融顆粒化された調合物及びこの調合物から製造された、放出が調節された投薬形 |
| PT1641456E (pt) | 2003-06-25 | 2010-06-01 | Lundbeck & Co As H | Gaboxadol para o tratamento de depressão e outros distúrbios afectivos |
| TW200528098A (en) * | 2003-12-18 | 2005-09-01 | Lundbeck & Co As H | Treatment of insomnia in human patients |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| EP1848420A4 (en) | 2005-01-28 | 2008-01-23 | Merck & Co Inc | POLYMORPHIC FORMS OF A GABAA AGONIST |
| US20080262029A1 (en) * | 2005-04-29 | 2008-10-23 | H. Lundbeck A/S | Acid and Base Salt Forms of Gaboxadol |
| ES2675544T3 (es) * | 2008-05-30 | 2018-07-11 | Psychogenics Inc. | Tratamiento para trastornos mentales y neurológicos |
| JP2012501301A (ja) * | 2008-09-01 | 2012-01-19 | ハー・ルンドベック・アクチエゼルスカベット | ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物 |
| CA2859174C (en) * | 2011-12-12 | 2019-03-05 | Orbis Biosciences, Inc. | Sustained release particle formulations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4315934A (en) * | 1979-09-24 | 1982-02-16 | Sandoz Ltd. | Organic compounds |
| DE19525598C2 (de) * | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| US6649186B1 (en) * | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
| JP2003510266A (ja) * | 1999-09-28 | 2003-03-18 | ハー・ルンドベック・アクチエゼルスカベット | 溶融顆粒化された調合物及びこの調合物から製造された、放出が調節された投薬形 |
| US6375982B1 (en) * | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
-
2002
- 2002-05-17 WO PCT/DK2002/000332 patent/WO2002094225A1/en active Application Filing
- 2002-05-17 NZ NZ547636A patent/NZ547636A/en unknown
- 2002-05-17 AR ARP020101839A patent/AR033896A1/es unknown
- 2002-05-17 PL PL02366541A patent/PL366541A1/xx not_active Application Discontinuation
- 2002-05-17 IL IL15873302A patent/IL158733A0/xx unknown
- 2002-05-17 SK SK1554-2003A patent/SK15542003A3/sk not_active Application Discontinuation
- 2002-05-17 BR BR0209834-2A patent/BR0209834A/pt not_active IP Right Cessation
- 2002-05-17 YU YU92103A patent/YU92103A/sh unknown
- 2002-05-17 JP JP2002590944A patent/JP2004530695A/ja active Pending
- 2002-05-17 EA EA200700703A patent/EA200700703A1/ru unknown
- 2002-05-17 KR KR10-2003-7015136A patent/KR20030097890A/ko not_active Application Discontinuation
- 2002-05-17 AU AU2002338855A patent/AU2002338855B2/en not_active Ceased
- 2002-05-17 US US10/478,983 patent/US20040157876A1/en not_active Abandoned
- 2002-05-17 CN CNA028104587A patent/CN1511026A/zh active Pending
- 2002-05-17 ME MEP-63/08A patent/MEP6308A/xx unknown
- 2002-05-17 HU HU0400051A patent/HUP0400051A2/hu unknown
- 2002-05-17 EA EA200301282A patent/EA009731B1/ru not_active IP Right Cessation
- 2002-05-17 MX MXPA03010596A patent/MXPA03010596A/es not_active Application Discontinuation
- 2002-05-17 EP EP02742834A patent/EP1389091A1/en not_active Ceased
- 2002-05-17 CA CA002447603A patent/CA2447603A1/en not_active Abandoned
- 2002-05-17 CZ CZ20033269A patent/CZ20033269A3/cs unknown
- 2002-05-17 UA UA20031110120A patent/UA80092C2/uk unknown
-
2003
- 2003-11-04 ZA ZA200308594A patent/ZA200308594B/en unknown
- 2003-11-10 IS IS7020A patent/IS7020A/is unknown
- 2003-11-19 NO NO20035146A patent/NO20035146L/no not_active Application Discontinuation
- 2003-11-21 HR HR20030950A patent/HRP20030950A2/hr not_active Application Discontinuation
- 2003-12-12 BG BG108441A patent/BG108441A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030097890A (ko) | 2003-12-31 |
| MEP6308A (xx) | 2010-02-10 |
| EP1389091A1 (en) | 2004-02-18 |
| YU92103A (sh) | 2006-05-25 |
| EA200700703A1 (ru) | 2007-08-31 |
| SK15542003A3 (sk) | 2004-05-04 |
| BG108441A (en) | 2005-02-28 |
| NO20035146D0 (no) | 2003-11-19 |
| NZ547636A (en) | 2008-03-28 |
| MXPA03010596A (es) | 2004-03-09 |
| NO20035146L (no) | 2003-11-19 |
| HUP0400051A2 (hu) | 2004-04-28 |
| ZA200308594B (en) | 2004-11-04 |
| CZ20033269A3 (en) | 2004-03-17 |
| CA2447603A1 (en) | 2002-11-28 |
| WO2002094225A1 (en) | 2002-11-28 |
| JP2004530695A (ja) | 2004-10-07 |
| EA200301282A1 (ru) | 2004-04-29 |
| PL366541A1 (en) | 2005-02-07 |
| EA009731B1 (ru) | 2008-02-28 |
| IL158733A0 (en) | 2004-05-12 |
| HRP20030950A2 (en) | 2005-08-31 |
| IS7020A (is) | 2003-11-10 |
| BR0209834A (pt) | 2004-06-15 |
| CN1511026A (zh) | 2004-07-07 |
| AU2002338855B2 (en) | 2007-08-16 |
| AR033896A1 (es) | 2004-01-07 |
| US20040157876A1 (en) | 2004-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006226293B2 (en) | Solubilized ibuprofen | |
| AU750978B2 (en) | Polymorphic crystalline forms of celecoxib | |
| JP4875001B2 (ja) | アリピプラゾールの湿式造粒医薬組成物 | |
| CZ20013376A3 (cs) | Způsob výroby nehygroskopických solí L(-)-karnitinu | |
| JP2002509886A (ja) | メロキシカムの経口投与用新規ガレヌス調製物 | |
| UA80092C2 (en) | Granular preparations of gaboxadol, process for the preparation thereof and pharmaceutical composition | |
| JP2001518503A (ja) | ５−（２−エチル−２ｈ−テトラゾール−５−イル）−１−メチル−１，２，３，６−テトラヒドロピリジンの粒状調合物 | |
| JP2003531153A (ja) | シタロプラムを含有する薬学的調合物 | |
| RU2123841C1 (ru) | Способ получения фармацевтической композиции, фармацевтическая композиция, фармацевтический препарат, способ получения фармацевтического препарата | |
| EP2603288A1 (en) | Pharmaceutical granulate comprising imatinib mesylate | |
| AU2002338855A1 (en) | Granular preparations of gaboxadol | |
| JP2003518486A (ja) | トラマドール・ハイドロクロライドを含む放出の調整された医薬組成物およびその調製方法 | |
| JP2841857B2 (ja) | 長期間安定な経口用医薬製剤 | |
| RU2183119C1 (ru) | Фармацевтическая композиция, обладающая спазмолитической активностью, способ ее получения | |
| SK9912003A3 (en) | Pharmaceutical composition containing citalopram | |
| JP3232687B2 (ja) | イミダプリル含有製剤 | |
| Gawshinde | Formulation, development and evaluation of paracetamol tablet by moisture activated dry granulation (MADG) process | |
| PL236614B1 (pl) | Kompozycja farmaceutyczna zawierająca febuksostat oraz sposób jej wytwarzania | |
| SK285964B6 (sk) | Liečivý prípravok obsahujúci fexofenadín hydrochlorid a spôsob jeho prípravy |